Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 3, 2011

University of Oxford to Sequence Whole Genomes of 500 People Using Illumina Technology

  • Clinicians and geneticists at the University of Oxford have decided to use Illumina’s HiSeq™ 2000 systems to sequence the whole genomes of 500 individuals afflicted with life-threatening diseases. The project will focus primarily on cancer, immunological disorders, and rare Mendelian diseases, all involving mutations difficult or impossible to discover through standard genetic tests.

    "Our collaboration with Illumina, studying over a hundred different diseases, will allow us to explore the value of whole-genome sequencing in clinical medicine in informing diagnosis and treatment decisions for patients,” states Peter Donnelly, director of the Wellcome Trust Centre for Human Genetics at the University of Oxford.

    Illumina will sequence 100 genomes at its Chesterford site in the U.K., while the remaining 400 genomes will be sequenced using HiSeq 2000 systems at the Wellcome Trust Centre for Human Genetics. Introduced to the market in January 2010, Illumina's high-throughput HiSeq 2000 reportely offers a five-fold improvement in throughput over second-generation sequencing technologies.

    Already, information obtained by sequencing a family’s whole genomes has revealed a genetic mutation believed responsible for a life-threatening cranial developmental defect in a four-year-old girl. According to Illumina, Oxford clinicians have used the whole-genome sequence information to identify mutations that, when validated, enable them to properly diagnose the disorder, evaluate potential healthcare options, and provide her family with genetic counseling.

    As a prelude to the sequencing effort, the Oxford team solicited cases from the university’s clinical community to learn about the range of patients and diseases most likely to benefit directly from whole-genome sequencing.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »